Compare MGRC & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGRC | SRPT |
|---|---|---|
| Founded | 1979 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 1995 | 2000 |
| Metric | MGRC | SRPT |
|---|---|---|
| Price | $109.68 | $17.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 29 |
| Target Price | ★ $141.50 | $25.85 |
| AVG Volume (30 Days) | 247.6K | ★ 2.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.10 | ★ 2.88 |
| Revenue | $944,235,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $4.69 | N/A |
| Revenue Next Year | $4.81 | N/A |
| P/E Ratio | $100.19 | ★ $5.78 |
| Revenue Growth | 3.65 | ★ 15.58 |
| 52 Week Low | $94.99 | $10.42 |
| 52 Week High | $128.41 | $43.92 |
| Indicator | MGRC | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 34.11 |
| Support Level | $108.76 | $16.09 |
| Resistance Level | $111.26 | $19.32 |
| Average True Range (ATR) | 2.62 | 1.14 |
| MACD | -0.54 | -0.48 |
| Stochastic Oscillator | 22.62 | 8.24 |
McGrath RentCorp is a diversified business-to-business rental company with three rental divisions: relocatable modular buildings, portable storage containers, and electronic test equipment. It comprises four reportable business segments, namely the Modular Building segment (Mobile Modular), which generates maximum revenue; the Portable Storage segment (Portable Storage); the Electronic Test Equipment segment (TRS-RenTelco); and its classroom manufacturing business (Enviroplex), which sells modular buildings used as classrooms in California. The company generates its revenues mainly from the rental of its equipment under operating leases, with sales of equipment occurring in the normal course of business.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.